29 sep 25   genedrive plc - result of retail offer genedrive plc | gdr | 0.2 0.02 11.1% | mkt cap: 2.56m    rns number : 1101b genedrive plc 29 september 2025   this announcement and the information contained herein is restricted and is not for publication, release or distribution, directly or indirectly, in whole or in part, in or into the united states of america, australia, canada, japan or the republic of south africa or in or into any other jurisdiction where to do so might constitute a violation or breach of any applicable law or regulation. further, this announcement is made for information purposes only and does not constitute an offer for sale or subscription of any securities in the company or contain any invitation, solicitation, recommendation, offer or advice to any person subscribe for or otherwise acquire shares in genedrive plc in any jurisdiction. genedrive plc   ("genedrive", the "group" or the "company")   result of retail offer   manchester, uk - 29 september 2025: genedrive plc (lse: gdr), the point of care pharmacogenetic testing company, is pleased to announce that it has conditionally raised gross proceeds of approximately £0.33 million through the retail offer. the terms and conditions of the retail offer were announced by the company at 5.03 p.m. on 23 september 2025.    total demand received through the retail offer was approximately £0.68 million which exceeded the total amount available to be allocated under the retail offer which was capped at approximately £0.33 million. this cap includes the 10 per cent. scale up mechanism which given the level of retail shareholder demand has been exercised.  accordingly, a total of 164,875,000 retail offer shares are therefore expected to be issued pursuant to the retail offer including 38,750,000 retail offer shares subscribed for by three directors of the company as detailed in the completion of placing announcement which was issued by the company on 24 september 2025.   additional demand of £100,000 which was flagged in the completion of placing announcement has now been accepted into the conditional placing following the entering into of binding commitment with the investor. accordingly, the conditional placing and the retail offer have together conditionally raised a total of approximately £2.82 million through the issue of 1,248,750,000 conditional placing shares and 164,875,000 retail offer shares. the firm placing completed on 26 september 2025 and raised gross proceeds of £800,000 for the company through the issue of 400,000,000 firm placing shares.    as a result, the company has conditionally raised a total of approximately £3.62 million via the placing and the retail offer which exceeds the required minimum amount needed to be raised in order for the fundraising (other than the firm placing which has already completed) to become unconditional.   the conditional placing and the retail offer are still conditional on, inter alia, the passing of resolutions 1 and 2 at the general meeting (expected to be convened for 15 october 2025 and second admission occurring no later than 8.00 a.m. on 16 october 2025 (or such later time and/or date as may be agreed between the company, peel hunt and allenby capital being no later than 8.00 a.m. on 30 october 2025).   application has been made to the london stock exchange for the admission of 1,413,625,000 new ordinary shares to trading on aim ("second admission"). this comprises: (i) 1,248,750,000 conditional placing shares; and (ii) 164,875,000 retail offer shares. these new ordinary shares will rank pari passu with the existing ordinary shares.   subject to, inter alia, the passing of the resolutions, a further announcement will be made in due course in relation to the total number of voting rights of the company from second admission.   unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the applicable announcement of the fundraising made by the company on 23 september 2025.   enquiries:   genedrive plc +44 (0) 161 989 0245 dr gino miele (ceo) russ shaw (cfo)    peel hunt llp - nominated adviser, joint broker and joint bookrunner                 +44 (0) 20 7148 8900 james steel / benjamin harris (investment banking)   sohail akbar / nicholas wilks (ecm)       allenby capital limited - joint broker and joint bookrunner nick athanas / vivek bhardwaj (corporate finance) amrit nahal / kelly gardiner (sales & corporate broking)   +44 (0)20 3328 5656 info@allenbycapital.com   walbrook pr - financial pr & ir adviser +44 (0) 20 7933 8780 paul mcmanus / anna dunphy or genedrive@walbrookpr.com                                                                                                                about genedrive plc (http://www.genedriveplc.com)            genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. this helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. based in the uk, the company is at the forefront of point of care pharmacogenetic testing in emergency healthcare. pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. the company has launched its two flagship products, the genedrive® mt-rnr1 id kit and the genedrive® cyp2c19 id kit, both developed and validated in collaboration with nhs partners and deployed on its point of care thermocycler platform. both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. the directors believe the genedrive® mt-rnr1 id kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. its cyp2c19 id kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. both tests have undergone review by the national institute for health and care clinical excellence ("nice") and have been recommended for use in the uk nhs. the company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic m&a, and operates out of its facilities in manchester.     important notices and disclaimer this announcement including its appendices (together, this "announcement") and the information contained in it is not for publication, release, transmission distribution or forwarding, in whole or in part, directly or indirectly, in or into the united states of america, australia, canada, japan or the republic of south africa or any other jurisdiction in which publication, release or distribution would be unlawful. this announcement is for information purposes only and does not constitute an offer to sell or issue, or the solicitation of an offer to buy, acquire or subscribe for shares in the capital of the company in the united states of america, australia, canada, japan or the republic of south africa or any other state or jurisdiction where to do so would be unlawful. any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions. this announcement has not been approved by london stock exchange or by any other securities exchange.    the new ordinary shares and corresponding warrants, have not been, and will not be, registered under the u.s. securities act of 1933, as amended (the "securities act") or with any securities regulatory authority of any state or other jurisdiction of the united states of america and may not be offered, sold, pledged, taken up, exercised, resold, renounced, transferred or delivered, directly or indirectly, in or into the united states of america absent registration under the securities act, except pursuant to an exemption from the registration requirements of the securities act and in compliance with any applicable securities laws of any state or other jurisdiction of the united states of america. the placing shares are being offered and sold by the company outside of the united states of america in offshore transactions as defined in, and pursuant to, regulation s under the securities act.   this announcement is not being distributed by, nor has it been approved for the purposes of section 21 of the financial services and markets act 2000, as amended ("fsma"), by a person authorised under fsma.  this announcement is being directed to persons in the united kingdom only in circumstances in which section 21(1) of fsma does not apply.   members of the public are not eligible to take part in the placing.  this announcement is for information purposes only and is directed only at persons who are: (1) in member states of the european economic area, qualified investors as defined in article 2(e) of the prospectus regulation (eu) 2017/1129 (the "eu prospectus regulation"); (2) in the united kingdom, qualified investors as defined in article 2(e) of prospectus regulation (eu) 2017/1129 as it forms part of uk domestic law by virtue of the european union (withdrawal) act 2018, as amended (the "uk prospectus regulation"), who (a) fall within article 19(5) ("investment professionals") of the financial services and markets act 2000 (financial promotion) order 2005, as amended (the "order"), or (b) fall within article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the order; or (3) are persons to whom it may otherwise be lawfully communicated; (all such persons together being referred to as "relevant persons"). this announcement and the terms and conditions set out herein must not be acted on or relied on by persons who are not relevant persons. persons distributing this announcement must satisfy themselves that it is lawful to do so. any investment or investment activity to which this announcement and the terms and conditions set out herein relates is available only to relevant persons and will be engaged in only with relevant persons.   the new ordinary shares have not been approved, disapproved or recommended by the u.s. securities and exchange commission, any state securities commission in the united states of america or any other u.s. regulatory authority, nor have any of the foregoing authorities passed upon or endorsed the merits of the offering of new ordinary shares. subject to certain exceptions, the securities referred to herein may not be offered or sold in the united states of america, australia, canada, japan or the republic of south africa or to, or for the account or benefit of, any national, resident or citizen of the united states of america, australia, canada, japan or the republic of south africa.   no public offering of securities is being made in the united kingdom, the united states of america or any other jurisdiction. offers of the new ordinary shares will either be made pursuant to an exemption under the eu prospectus regulation and the uk prospectus regulation (as such terms are defined above) from the requirement to produce a prospectus or otherwise in circumstances not resulting in an offer of transferable securities to the public under section 102b of fsma.   this announcement has been issued by, and is the sole responsibility of, the company. no representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the directors or the company, or by any of its or their respective partners, employees, advisers, affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.   none of the information in the announcement has been independently verified or approved by peel hunt, allenby capital or any of their respective partners, directors, officers, employees, advisers, consultants, affiliates or agents.   peel hunt, which is authorised and regulated in the united kingdom by the fca is acting as nominated adviser, joint bookrunner and joint broker to the company and no one else in connection with the placing and is not acting for and will not be responsible to any person other than the company for providing the protections afforded to its clients or for providing advice in relation to the placing. peel hunt's responsibilities as the company's nominated adviser under the aim rules for nominated advisers are owed solely to london stock exchange and are not owed to the company or to any director or to any other person in respect of his decision to acquire shares in the company in reliance on any part of this announcement.   allenby capital, which is authorised and regulated in the united kingdom by the fca is acting as joint bookrunner and joint broker to the company and no one else in connection with the placing and is not acting for and will not be responsible to any person other than the company for providing the protections afforded to its clients or for providing advice in relation to the placing.   except as required under applicable law, neither peel hunt, allenby capital nor any of their respective directors, officers, partners, members, employees, advisers, affiliates or agents assume or accept any responsibility whatsoever for the contents of the information contained in this announcement or for any other statement made or purported to be made by or on behalf of peel hunt, allenby capital or any of their affiliates in connection with the company, the new ordinary shares or the placing.  peel hunt, allenby capital and each of their respective directors, officers, partners, members, employees, advisers, affiliates and agents accordingly disclaim all and any responsibility and liability whatsoever, whether arising in tort, contract or otherwise (save as referred to above) in respect of any statements or other information contained in this announcement and no representation or warranty, express or implied, is made by peel hunt, allenby capital or any of their respective directors, officers, partners, employees, advisers, affiliates or agents as to the accuracy, completeness or sufficiency of the information contained in this announcement.   the distribution of this announcement and/or the placing in certain jurisdictions may be restricted by law. no action has been taken by the company, peel hunt, allenby capital or any of their respective affiliates that would, or which is intended to, permit an offering of the new ordinary shares in any jurisdiction or result in the possession or distribution of this announcement or any other offering or publicity material relating to new ordinary shares in any jurisdiction where action for that purpose is required.    this announcement does not constitute a recommendation concerning any investor's option with respect to the placing. each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information. the price and value of securities can go down as well as up. past performance is not a guide to future performance.   the contents of this announcement are not to be construed as legal, business, financial or tax advice. each investor or prospective investor should consult with his or her or its own legal adviser, business adviser, financial adviser or tax adviser for legal, financial, business or tax advice.   persons (including without limitation, nominees and trustees) who have a contractual right or other legal obligations to forward a copy of this announcement should seek appropriate advice before taking any action.   neither the content of the company's website nor any website accessible by hyperlinks on the company's website is incorporated in, or forms part of, this announcement.   product governance requirements solely for the purposes of the product governance requirements of chapter 3 of the fca handbook product intervention and product governance sourcebook (the "uk product governance requirements") and/or any equivalent requirements elsewhere to the extent determined to be applicable, and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the uk product governance requirements and/or any equivalent requirements elsewhere to the extent determined to be applicable, may otherwise have with respect thereto, the placing shares have been subject to a product approval process, which has determined that the placing shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each defined in chapter 3 of the fca handbook conduct of business sourcebook; and (ii) eligible for distribution through all permitted distribution channels (the "target market assessment"). notwithstanding the target market assessment, distributors should note that: the price of the placing shares may decline and investors could lose all or part of their investment; the placing shares offer no guaranteed income and no capital protection; and an investment in the placing shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. the target market assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the placing. furthermore, it is noted that, notwithstanding the target market assessment, peel hunt and allenby capital will only procure investors who meet the criteria of professional clients and eligible counterparties.   for the avoidance of doubt, the target market assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of chapters 9a or 10a respectively of the fca handbook conduct of business sourcebook; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the placing shares.   each distributor is responsible for undertaking its own target market assessment in respect of the placing shares and determining appropriate distribution channels. forward looking statements   this announcement contains "forward-looking statements" which include all statements (other than statements of historical facts) including, without limitation, those regarding the group's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could" or "similar" expressions or negatives thereof. such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the company's control that could cause the actual results, performance or achievements of the group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. such forward-looking statements are based on numerous assumptions regarding the group's present and future business strategies and the environment in which the group will operate in the future. these forward-looking statements speak only as at the date of this announcement. the company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the aim rules for companies.   no statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the company for the current or future years would necessarily match or exceed the historical published earnings per share of the company.   this announcement does not constitute a recommendation concerning any investor's investment decision with respect to the placing. in addition, this announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect that may be associated with an investment in the placing shares.   any investment decisions to buy placing shares in the placing must be made solely on the basis of publicly available information which has not been independently verified by peel hunt or allenby capital.   the new ordinary shares will not be admitted to trading on any stock exchange other than the aim market of the london stock exchange.   the price and value of securities can go down as well as up. past performance is not a guide to future performance.   this information is provided by rns, the news service of the london stock exchange. rns is approved by the financial conduct authority to act as a primary information provider in the united kingdom. terms and conditions relating to the use and distribution of this information may apply. for further information, please contact rns@lseg.com or visit www.rns.com.  rns may use your ip address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. for further information about how rns and the london stock exchange use the personal data you provide us, please see our privacy policy.   end   roibvllleklebbe return to news summary

Label: Gestiegen